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Abstract
Background: Cellular function is regulated by the balance of stringently regulated amounts of mRNA. Previous
reports revealed that RNA polymerase II (RNAPII), which transcribes mRNA, can be classified into the pausing state
and the active transcription state according to the phosphorylation state of RPB1, the catalytic subunit of RNAPII.
However, genome-wide association between mRNA expression level and the phosphorylation state of RNAPII is
unclear. While the functional importance of pausing genes is clear, such as in mouse Embryonic Stem cells for
differentiation, understanding this association is critical for distinguishing pausing genes from active transcribing
genes in expression profiling data, such as microarrays and RNAseq. Therefore, we examined the correlation
between the phosphorylation of RNAPII and mRNA expression levels using a combined analysis by ChIPseq and
RNAseq.
Results: We first performed a precise quantitative measurement of mRNA by performing an optimized calculation
in RNAseq. We then visualized the recruitment of various phosphorylated RNAPIIs, such as Ser2P and Ser5P. A
combined analysis using optimized RNAseq and ChIPseq for phosphorylated RNAPII revealed that mRNA levels
correlate with the various phosphorylation states of RNAPII.
Conclusions: We demonstrated that the amount of mRNA is precisely reflected by the phased phosphorylation of
Ser2 and Ser5. In particular, even the most “pausing” genes, for which only Ser5 is phosphorylated, were detectable
at a certain level of mRNA. Our analysis indicated that the complexity of quantitative regulation of mRNA levels
could be classified into three categories according to the phosphorylation state of RNAPII.
Background
Cellular function is accomplished by the accurate, regu-
lated transcription of genes in the genome. The quantity
of transcribed mRNA of protein-coding genes varies, and
the regulation of transcription is carried out by a wide
variety of nuclear factors on the chromatin structure.
One of the key regulatory mechanisms is the control of
the activation of RNA polymerase II (RNAPII) [1].
RNAPII transcribes all protein-coding genes and many
non-coding genes, and the activity of RNAPII correlates
with the phosphorylation state of RPB1, the large cataly-
tic subunit of RNAPII [2]. RPB1 has an unusual C-
terminal domain (CTD) that consists of repeats of the
heptapeptide consensus sequence N-Tyr1-Ser2-Pro3-
Thr4-Ser5-Pro6-Ser7-C, of which there are 52 copies in
mammals [3]. The amino acids in these repeats are
potential targets for modification, such as phosphoryla-
tion and glycosylation. During transcriptional regulation,
free hypophosphorylated RNAPII is recruited to gene
promoters. RNAPII’s escape from the promoter requires
TFIIH, a general transcription factor that mediates
phosphorylation of CTD Ser5 [4]. After promoter
escape, RNAPII can move downstream of the transcrip-
tion start site (TSS) [5]; however, pausing factors, such
as NELF and DSIF, prevent productive elongation of
mRNA [6]. This phenomenon is known as promoter
proximal pausing [7]. Productive elongation of mRNA is
coupled with phosphorylation of the CTD Ser2 residue
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[8]. The influence of promoter proximal pausing of
RNAPII may contribute to the control of gene expres-
sion levels [9-11]. It is possible that full length mRNA
cannot be detected because of pausing, and that a wide
variety of expression levels, including high expression,
are regulated by pause site entry and escape of RNAPII
[7]. Recent studies revealed that RNAPII could bind to
the promoter region of inactive genes in human fibro-
blasts [9], as well as in ES cells [10]. Additionally, in
mouse ES cells, Ser5 phosphorylated and Ser2 unpho-
sphorylated RNAPII accumulates around the TSSs in
bivalent genes [11]. These genes, as differentiation mar-
kers, can be detected at low levels, despite their associa-
tion with pluripotency [12]. High throughput
sequencing technology and cDNA analysis have emerged
as revolutionary tools in recent years, but whether these
sequencing data come from active transcription or paus-
ing state genes, and the genome-wide phosphorylation
status of RNAPII in vivo, have not been studied. Several
genes in which RNAPII is in the pausing state play key
role in differentiation [12]; therefore, understanding the
correlation of RNAseq and RNAPII phosphorylation
state is very important. To evaluate the phosphorylation
status of RNAPII for all genes identified with RNAseq,
we have to exclude free RNAPII, in which Ser2 and
Ser5 residues are not phosphorylated, and distinguish
actively transcribed genes, for which both of Ser2 and
Ser5 residues are phosphorylated, from pausing state
genes, for which Ser5 residues are only phosphorylated.
Evaluation of the relationship between the phosphoryla-
tion state of RNAPII and mRNA expression level will
permit the identification of those genes that are actively
transcribed and those that are pausing.
A variety of techniques have been developed to quan-
tify and analyze gene expression levels, such as northern
blotting, RT-qPCR, SAGE, and microarrays. Recently
emerged deep sequencers enable the analysis of mRNA
expression with much less bias compared with previous
technologies, by reading tens of millions of tags in a sin-
gle run (RNAseq) [13]. RNAseq can clarify the amount
of previously identified transcripts [14], identify novel
transcripts [15], and analyze tissue-specific alternative
splicing [16]. RNAseq is 1,000 times more sensitive than
microarrays for quantifying transcripts, and appears to
be the best currently available tool for the evaluation of
mRNA [17]. However, RNAseq has its own limitations.
One such limitation is the need for reference sequences.
The deep sequencer examines 25-200 bp short frag-
ments, unlike previous technologies, and sequences tens
of millions of fragments in a single run. These frag-
ments, also known as ‘reads’, are mapped to a reference
transcriptome to identify gene expression. However,
because the transcriptomes are incomplete, even for
well-studied species such as human and mouse, analysis
of RNAseq data is restricted by the reference sequence,
and requires another calculation to identify novel tran-
scripts. TopHat [18] does not depend on a reference
transcriptome, and provided a new way to evaluate
novel transcripts, including new splicing sites. In addi-
tion, Cufflinks [19] can map reads to a reference gen-
ome and identify all transcripts quantitatively per
kilobase of nucleotides and considers splicing. The weak
point of quantification by these mapping techniques is
the comparatively short sequence tag used to map to
the reference genome. Success in mapping a sequence
depends on the structure of the mRNA; it may have
homologs that have a common structure, which may
introduce bias to the statistical results. Therefore, to
overcome these biases, it is necessary to use not only
unique information, where one tag is mapped to one
genomic region, but also multiple hit information,
where one tag is mapped to two or more genomic
regions. In TopHat the parameter ‘Max multihits’ con-
trols how many regions one tag is allowed to map to,
thereby optimizing mapping efficiency. However, a
detailed evaluation of the influence of this parameter
setting on the identification of mRNA has not been
performed.
Thus, we used a deep sequencer to clarify how various
mRNA expression levels are controlled, by analyzing the
regulation of RNAPII through CTD phosphorylation.
We categorized gene expression by identifying the phos-
phorylation control of RNAPII for all genes. In addition,
by combining these data with genome-wide gene expres-
sion data that were obtained from RNAseq using the
optimized ‘Max multihits’ parameter, we clarified the
correlation between various mRNA expressions and
RNAPII phosphorylation.
Results and Discussion
The accuracy of RNASeq is improved by permitting a
small number of ‘multihits’
To understand the transcriptional regulation mechan-
isms mediated by RNAPII, it was necessary to evaluate
mRNA expression as accurately and quantitatively as
possible. Many mRNAs possess high sequence similarity
to their homologs in the genome, and when an
increased number of ‘Max multihits’, one of parameters
of TopHat, are permitted, we predicted that a greater
number of genes would be identified. Figure 1A shows
RNAseq analysis data in Hela cells, a popular human
cell line for which there are abundant existing microar-
ray data and reference sequence information, and shows
the number of FPKM > 0 genes (FPKM: fragments per
kilobase of exon per million fragments mapped, calcu-
lated by both TopHat and Cufflinks) identified with
increasing Max multihits. It is clear that higher numbers
of genes are identified when ‘Max multihits’ is increased,
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which means the sequences of two or more genes are
taken forward for analysis. Figure 1B shows Spearman’s
correlation coefficient plotted against increasing ‘Max
multihits’ for three previously published expression
microarray data sets: GSM23372 [20], GSM161670 [21],
and GSM246123 [22], and the value of FPKM. Though
they are independent data sets, they show a high level of
correlation that is not inferior compared with previously
published analyses [17]. The correlation coefficient
shows a tendency to rise with increasing ‘Max multihits’.
However, when ‘Max multihits’ becomes ten or more,
both the number of identified genes (Figure 1A) and the
correlation coefficient between the expression microar-
ray and RNAseq (Figure 1B) hardly changes. This takes
into account the fact that if a moderate multihit limit
were not allowed, homologous sites would be excluded
from RNAseq analysis. Conversely, increasing multihits
too far introduces the danger of counting genes that
were not originally expressed. To identify any negative
influences of increasing ‘Max multihits’, we analyzed
RNAseq data taking into account splicing. TopHat per-
forms an alignment to the genome by dividing the
cDNA sequence, and when it matches the genome,
TopHat presumes that place to be a splice junction. Fig-
ure 1C shows the number of splice junctions found by
TopHat in known genes or FPKM > 0 genes plotted
against increasing ‘Max multihits’. The proportion of
splice sites found in genes other than already-known
genes, or FPKM > 0 genes, increases as ‘Max multihits’
increases. In addition, we examined the influence of
increasing Max multihits (1, 10, or 100 permitted) on
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Figure 1 Plots to assess the effect of the parameter ‘Max multihits’ (X-axis). ‘Max multihits’ is a TopHat parameter that indicates how many
times one tag is permitted to be aligned. (a) Number of genes found by RNAseq (Y-axis) against ‘Max multihits’. (b) Spearman’s correlation
between microarrays (GSM23372, GSM161670, and GSM246123) and RNAseq. (c) Y-axis indicates how many splicing sites found in TopHat were
included in known genes or FPKM > 0 genes. (d) Histogram showing the distribution of FPKM. As the number of permitted ‘Max multihits’
increased, the quantity of genes with small FPKM values increased (black arrows).
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(15 groups, FPKM). The figure shows that the only sig-
nificant change was an increase in the number of genes
in the FPKM 0-0.5 group. From these results, we deter-
mined that the optimum setting for ‘Max multihits’ was
10. This identified the maximum number of genes, satu-
rated the correlation between RNAseq and past expres-
sion microarray data sets, and reduced the possibility
false positives. The accuracy of this optimization was
reinforced by performing RT-PCR on genes with a small
FPKM value (0.05-1.97) when ‘Max multihits’ was set to
10, and confirming the mRNA expression (Additional
File 1, Figure S1).
The distribution of phosphorylated RNAPII
It has been reported that RNAPII transcribing activity
correlates with the phosphorylation status of RNAPII
(Figure 2A) [7]. Systematic and genome wide evaluation
for the separation of pausing and active transcription
states of RNAPII has not been done with the most fre-
quently used antibodies, which recognize the phosphory-
lation state of RNAPII. Some of these antibodies were
characterized as having limited activity to specific phos-
phorylation states [23]. Thus, we produced antibodies
that specifically recognized Ser-2-phosphorylated
(Ser2P) or Ser-5-phosphorylated (Ser5P) RNAPII to ana-
lyze the relationship between transcriptional levels and
RNAPII phosphorylation for ChIPseq. Stock et al. (2007)
showed that RNAPII could be classified into hyperpho-
sphorylated RNAPII, in which Ser2 and/or Ser5 residues
of the C-terminal domain are phosphorylated, and hypo-
phosphorylated RNAPII, in which neither were phos-
phorylated, by western blotting analysis. Figure 2B
shows that, in whole cell lysate of Hela cells, the antibo-
dies to Ser2P and Ser5P specifically recognized hyper-
phosphorylated RNAPII, while antibody sc-899, which
was raised against the N-terminus of RNAPII, recog-
nized RNAPII regardless of its phosphorylation status.
Monoclonal antibodies against the CTD can be influ-
enced by the context of the antigen and the phosphory-
lation status of surrounding peptides [23]. Thus, to
confirm the specificity of our antibodies to phosphoryla-




































































































position relative to gene body
Figure 2 Generation and assessment of anti-phosphorylated Ser2/Ser5 RNAPII antibodies. (a) RNAPII was categorized by the
phosphorylation status of its C-terminal domain (CTD). (a) Free RNAPII was hypophosphorylated in its CTD residues, and recruited to the
promoter, where TFIIH phosphorylates Ser5 residues. Ser5-phosphorylated RNAPII progresses to the pausing site, but it is halted by negative
elongation factors. Phosphorylation of Ser2 allows active transcription. Recent evidence suggests that several pausing genes produce full-length
transcripts at low levels. (b) Reactivity of different RNAPII antibodies against hyper- and hypophosphorylated RNAP2 was assessed by
immunoblotting. (c) The average Ser2/Ser5 phosphorylated RNAP2 enrichment tags per one gene from ChIPseq data, normalized to input by
Peakseq, were summed according to their shifted positions, with the definition that gene length was from 0 to 1. Where 0 represents the
transcription start site and 1 represents the transcription end site.
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CTD repetitive sequence (N-Tyr-Ser-Pro-Thr-Ser-Pro-
Ser-C) phosphorylated at Ser2, Ser5, and Ser7 (singly or
in combination) as an antigen (Table 1). The antibody
to Ser2P recognized only Ser2P of RNAPII and was
hardly influenced by phosphorylation of surrounding
Ser5 or Ser7. By contrast, the antibody against Ser5P
was influenced by Ser7P on the downstream side, but
not by Ser2P. Thus, our antibodies specifically recog-
nized Ser2P and Ser5P of the CTD under suitable con-
ditions. Next, to evaluate the distribution of RNAPII on
the genome, ChIPseq (which uses chromatin immuno-
precipitation (ChIP) and deep sequencing to analyze
DNA-protein interactions) was performed with these
antibodies. All genes containing a region that coincided
with part of a peak that was judged to be a significant
peak under the condition of false discovery rate (FDR) <
0.05 and P-value < 0.05 by Peakseq [24] were selected.
For these genes, using a previous model of analysis [25],
detected gene body tags of ChIPseq were confirmed for
all tags, and the total number of tags relative to input
per one gene was calculated. Figure 2C shows the anti-
body to Ser5P exclusively detects high peaks around the
transcription start site (TSS), and the antibody to Ser2P
detects high peaks over the entire gene body, particu-
larly around the transcription end site (TES). These
results agreed with those of a previous study [12]. While
relative tag count per one gene was almost the same for
anti-Ser2P and anti-Ser5P around the TES, the total of
relative tag count of Ser5P around the TSS was about
ten times higher than that of Ser2P. These results indi-
cate that these antibodies could distinguish between
hyperphosphorylated RNAPII in the promoter proximal
pausing state (Ser5P+, Ser2P-) and the active transcrip-
tion state (Ser5P+, Ser2P+), and they also indicate that
RNAPII performs genome wide movement, as previously
described [7].
RNASeq can detect the expression of most genes, even in
the “pausing” genes
In embryonic stem (ES) cells, Ser5-phosphorylated
RNAPII already exists on bivalent genes and pauses at
the promoter proximal region [12]. This may suggest
that pausing genes have a key role at the beginning of
differentiation. However, to date, no report has estab-
lished which phosphorylation state of RNAPII corre-
sponds to the gene expression identified by RNAseq.
How many genes defined as ‘pausing’ genes actually
express mRNA and how much mRNA from ‘pausing’
genes is transcribed is also still unclear. To examine
how many active transcribing genes and pausing genes
were identified by RNAseq, we constructed a Venn dia-
gram (Figure 3A, Additional File 2, Figure S2) from
ChIPseq and RNAseq data. When the parameter of
‘Max multihits’ was expanded, the genes detected only
by RNAseq, but not by RNAseq and ChIPseq, increased
(Additional File 2, Figure S2). Increasing multihits too
far introduces the risk of counting silent genes; there-
fore, we used the optimized parameter ‘Max multihits =
10’, and used genes with FPKM > 0. Peaks that con-
formed to P-value < 0.05 and FDR < 0.05 were assumed
to be positive peaks using Peakseq [24], a Peakcaller in
ChIPseq. Although an RNAPII that pauses around the
promoter could be bound only to the region upstream
of the TSS, a previous report demonstrated that a paus-
ing RNAPII extends over the coding region [12]. There-
fore, we defined that the association of Ser2- and/or
Ser5-phosphorylated RNAPII with a gene was positive
only when a part of the positive peak corresponded to a
part of the gene body, to prevent the risk that other
genes were mistakenly selected from very gene-dense
genomic regions. All 23,821 human genes defined by
RefSeq were evaluated. As a result, 14,954 genes (62.7%)
of all genes had an FPKM > 0 in RNAseq or were
judged to be positive for Ser2- and/or Ser5-phosphory-
lated RNAPII in ChIPseq.
Among 7,918 genes in which Ser2P is positive, 6,860
genes (87%) were assumed to be Ser5P positive too. On
the other hand, among the 11,590 genes in which Ser5P
is positive, 6,860 genes (59%) are assumed to be Ser2P
positive. This result indicates that Ser5 and Ser2 of RNA-
PII have to be sequentially phosphorylated for active
transcription, as described previously [26]. However,
1,058 genes (13%) are Ser2P positive only. When these
genes are observed in the UCSC genome browser (Uni-
versity of California, Santa Cruz) (Figure 3B), Ser2P sin-
gle positive genes appear in the comparatively gene-
dense areas. Moreover, when the ChIP-qPCR data were
verified (Figure 3C), for instance, for SOX15, which is
judged to be a Ser2P single positive, more Ser2P was
identified around the TSS than around the TES, although
the amount of Ser2P did gradually increase towards the
TES (Figure 2C). These results suggest that Ser2P single
positive genes are false positives caused by the influence
of surrounding genes or non-annotated transcripts in
these regions. RNAPII with an unphosphorylated CTD is
first recruited to a promoter region and is then released
Table 1 The composition of the CTD and the reactivity of
each antibody
CTD Peptide anti-Ser2P anti-Ser5P
unmodified SPTSPSYSPTSPSYSPTSPS - -
Ser2P SPTSPSYSphPTSPSYSPTSPS ++ -
Ser5P SPTSPSYSPTSphPSYSPTSPS - ++
Ser7P SPTSPSYSPTSPSphYSPTSPS - -
Ser2PSer5P SPTSPSYSphPTSphPSYSPTSPS + ++
Ser5PSer7P SPTSPSYSPTSphPSphYSPTSPS - -
Ser7PSer2P SPTSPSphYSphPTSPSYSPTSPS ++ -
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Figure 3 Expressed genes were categorized by the phosphorylation state of RNAPII. (a) A Venn diagram summarizing the overlap
between FPKM > 0 genes, Ser2P-RNAPII positive genes, and Ser5P-RNAPII positive genes. We defined the presence of RNAPII to be positive if
the region of the peak found by Peakseq overlapped the gene body. (b) Tags found by ChIPseq and peaks found by Peakseq (P-value < 0.05,
FDR < 0.05) were visualized on the UCSC Genome Browser. (c) The abundance of different phosphorylated forms of RNAPII at Ser2P and/or
Ser5P positive genes assessed by ChIP and qPCR at the coding region near the TSS and TES.
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when its Ser5 is phosphorylated. Active transcription is
then initiated when Ser2 is phosphorylated; however,
RNAPII keeps running until its termination, even if tran-
scription ends [27]. This results in the deterioration of
the resolution of ChIPseq and it may be one factor that
causes false positives in gene-dense areas. To overcome
this limitation, we set a criterion in which we scored a
peak as positive only when the peak extended over the
gene body. Although this may affect the detection of
RNAPII that is in the state of promoter proximal pausing,
Ser5-phosphorylated RNAPII that is pausing around the
TSS seems to be sufficiently detected when using this
condition (Figure 3A-C).
Interestingly, RNAseq detected highly expressed genes
not only in the state of active transcription (Ser5P+,
Ser2P+), but also in the state of promoter proximal
pausing (Ser5P+, Ser2P-), in the majority of FPKM > 0
genes. These results indicated that the phosphorylation
of Ser5 and Ser2 correlates with gene expression in two
stages. It also indicates that RNAseq, because of its high
sensitivity, disregards the background epigenetic expres-
sion adjustment machinery associated with RNAPII
phosphorylation. Some of the differentiation markers
that were Ser5P single positive showed low mRNA
expression in mouse embryonic stem cells [12]. How-
ever, we should take note of the expression of differen-
tiation markers, as interpreted by RNAseq, in stem cells,
because some of these genes could be identified as a
result of RNAseq’s high sensitivity.
Among the 13,462 genes which RNAseq judged to
have an FPKM value > 0, 11,156 genes (83%) are Ser2P
and/or Ser5P positive. The remaining 2,306 genes (17%)
with FPKM > 0 in RNAseq, were identified as neither
Ser2P nor Ser5P in ChIPseq. Among 12,648 genes
which ChIPseq judged to be Ser2P and/or Ser5P posi-
tive, 11,156 genes (88%) were FPKM > 0 genes in
RNAseq.
To further investigate functional relationship among
pausing/active genes and gene functions, we analyzed
significant associations using Gene ontology [28] and
Fishers’ exact test(Additional File 3, Table S1). Hun-
dreds of GO terms were calculated to be significant for
active genes, and some of GO terms associated with
mitochondorial genes were judged to be significant for
pausing genes. Neither calculation seemed to give signif-
icant enrichment of specific genes, except for house-
keepking genes.
Gene expression levels reflect the level of
phosphorylation of RNAPII
To assess how much the phosphorylation of the CTD of
RNAPII correlates with genome-wide gene expression,
we examined the amount of mRNA expression by RNA-
seq in each part of the Venn diagram (Figure 3A). To
validate results in independent data, expression microar-
ray data sets, GSM23372 [20], GSM161670 [21], and
GSM246123 [22], were evaluated at the same time. A
heatmap (Figure 4A) and a histogram (Figure 4B) were
then produced using the data of RNAseq and the
expression microarrays. The amount of mRNA expres-
sion was the highest in the area representing Ser2P and
Ser5P double positive by ChIPseq, and decreased in the
order of Ser5P single positive, Ser2P single positive, and
Ser2P/Ser5P double negative, for FPKM > 0 genes (Fig-
ure 4A, B). However, in genes judged to be FPKM = 0,
no high levels of expression were observed in any of the
three expression microarray data sets. In addition, we
extracted genes at random and performed qPCR to vali-
date the data (Figure 4C). qPCR generated similar
results to Figure 4A, and expression was confirmed for
all of the genes judged FPKM > 0 by RNAseq. The
amount of expression tended to decrease in the order of
Ser2P/Ser5P double positive, Ser5P single positive,
Ser2P single positive, and Ser2P/Ser5P double negative.
Moreover, qPCR confirmed the results for three of the
six FPKM = 0 genes (WDR69, SPATA9, GGN), despite
their low expression levels (Figure 4C). Generally, RNA-
seq seems to be more sensitive than ChIPseq for detect-
ing mRNA, because sequence tags of RNAseq
concentrate on exons, and more genes could be detected
by RNAseq than by ChIPseq (Figure 3A). However, the
results shown in Figure 4C indicate that some gene
expressions that could not be confirmed with RNAseq
were identified with ChIPseq. ChIPseq has the advan-
tage of being able to map RNAPII to an intron or UTR
that has few homologs and does not need to consider
splicing; therefore, for certain genes, ChIPseq could
have higher sensitivity than RNAseq. On the other
hand, we also examined whether there was a correlation
between the height of the peak of RNAPII and the
amount of mRNA (Figure 4D), but no such correlation
was found. These data indicated that in terms of the
quantification of the amount of mRNA, RNAseq has a
much higher sensitivity than ChIPseq.
RNAPII status can be classified into three categories for
transcribed genes
The analysis of expression data from RNAseq allowed us
to classify genes into Ser2P/Ser5P double positive, single
positive, and double negative, according to their differ-
ent levels of expression. However, this was only for the
data from peaks judged to have a P-value < 0.05 and
FDR < 0.05 according to ChIPseq, and did not assess
the comparison of accumulated amounts of tags in
ChIPseq nor tags accumulated in genes outside of this
peak. Thus, to re-evaluate the phosphorylation state of
RNAPII between these gene categories, we did not uti-
lize the threshold of P-value and FDR and counted tags
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Figure 4 mRNA expression level correlates with the phosphorylation of RNAPII. (a) Expressions of genes assessed by expression microarray
(left: GSM23372, middle left: GSM 161670, middle right: GSM246123) and RNAseq (right). Each column indicated classified genes by FPKM (= 0, or
> 0) and RNAPII Ser2P and Ser5P binding state. Only those genes that had microarray expression data were analyzed; thus, there were 1,225/
2,306 (53%) FPKM > 0/Ser2P(-)/Ser5P(-) genes, 348/588 (59%) FPKM > 0/Ser2P(+)/Ser5P(-) genes, 2,601/4,063 (64%) FPKM > 0/Ser2P(-)/Ser5P(+)
genes, 4,727/6,505 (73%) FPKM > 0/Ser2P(+)/Ser5P(+) genes, 198/470 (42%) FPKM = 0/Ser2P(+)/Ser5P(-) genes, 232/667 (35%) FPKM = 0/Ser2P
(-)/Ser5P(+) genes, 122/355 (34%) FPKM = 0/Ser2P(+)/Ser5P(+) genes, and 2,803 FPKM = 0/Ser2P(-)/Ser5P(-) genes available for analysis. Color key
indicates gene expression value, yellow: over 90 percentile, black: median, blue: 10 percentile. The number of genes that were assessed was
restricted by the microarray platform. (b) Histogram showing how many genes exist for each FPKM value. Y-axis indicates relative frequency in
each category (RNAseq(+), Ser2P(+ or -), Ser5P(+ or -). Significant peak shift of the distribution of gene expression is shown according to each
category. (c) Transcripts derived from genes that are categorized by Figure 3A were quantified by qPCR. The expressions of not only RNAseq(+)
genes, but also some RNAseq(-) ChIPseq(+) genes are confirmed. (d) Assessment of the correlation between peak height of ChIPseq and FPKM
value of RNAseq. Peak height for each gene was calculated by extracting the highest one that existed in the coding region. There is no obvious
correlation.
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in each part of the gene body that were covered by
Ser2P and/or Ser5P and how frequently they existed in
each gene. Figure 5 and Supplementary Figure S3 show
in which part of gene the Ser5P-associated tags accumu-
lated (Figure 5A, Additional File 4, Figure S3 A). The
data for Ser2P-associated tags are shown in Figure 5B
and Supplementary Figure S3 B, which assumes that
gene body is from 0 to 1. Considering Ser5P tag counts,
although FPKM > 0/Ser2P(-)/Ser5P(+) genes and FPKM
> 0/Ser2P(+)/Ser5P(+) genes have similar levels of Ser5P
tags around the TSS, of the number of Ser5P tags asso-
ciated with Ser5P single positive genes decreases around
the TES compared with Ser2P/Ser5P double positive.
Even if only the existence of Ser5P around the TSS and
TES is considered, the classification of our gene groups
clearly distinguishes two states of RNAPII, i.e. promoter
proximal pausing and active transcription. Moreover,
the genes which RNAseq judged FPKM > 0 and ChIP-
seq judged not to be Ser5P positive, because of the con-
dition of P-value < 0.05 and FDR < 0.05, have Ser5P
around the TSS compared with FPKM = 0/Ser2P
(-)/Ser5P(-) genes, though at a low level, when the tags
are collected and counted.
When tags were summed for genes with FPKM > 0/
Ser2P(+)/Ser5P(-), the number of Ser2P tags tended to
be high (Additional File 4, Figure S3 B). However, for
these genes, the tag count outside of the gene (X axis is
more than 1 or less than 0) for Ser2P and Ser5P are
also higher than for other gene categories, and this may
indicate that they were picked up from the background
noise generated by surrounding genes. The Ser5P tags
showed a small peak around the TSS of these genes
(Additional File 4, Figure S3 A), and when the back-
ground was excluded, the shape of the graph obtained
from FPKM > 0/Ser2P(+)/Ser5P(-) genes was approxi-
mately the same as that from FPKM > 0/Ser2P(-)/Ser5P
(-). These results suggest that the genes whose expres-
sion is confirmed by RNAseq can be classified into
three categories by combining ChIPseq data concerning
Ser2P/Ser5P: ‘High pausing, High elongation (Ser5P+,
Ser2P+)’, ‘High pausing, Low elongation (Ser5P+, Ser2P-
)’, and ‘Low pausing, Low elongation (Ser5P-, Ser2P-)’.
Control of mRNA expression is correlated to phased
phosphorylation of Ser2 and Ser5
The amount of mRNA expression of the genes grouped
by phased phosphorylation of Ser2 and Ser5 of RNAPII
had a tendency to increase with the level of phosphory-
lation, leading the predicted three category mode: ‘High
pausing, High elongation’, ‘High pausing, Low elonga-
tion’, and ‘Low pausing, Low elongation’. Thus, a gene
could be categorized by its FPKM value using logistic
regression analysis. 13,462 genes judged to have FPKM
values > 0 by RNAseq became the object of the analysis.
As mentioned before, false positives could arise by the
influence of surrounding genes, and was thought to be
about 588 genes (Ser2P single positive); therefore, these
genes were counted in this analysis in addition to the
Ser2P/Ser5P double negative group. Whole model test
and parameter estimates are shown in Table 2. In addi-
tion, the phosphorylation status of Ser2 and/or Ser5 of
RNAPII was observed for each gene examined according
to the FPKM value, and a probability plot was produced
(Figure 6). As the value of FPKM obtained by RNAseq
rises, the probability that RNAPII is phosphorylated (as
judged by ChIPseq; P-value < 0.05, FDR < 0.05) rises.
Finally, half of the genes with an FPKM value of about 0










































































































position relative to gene body position relative to gene body
Figure 5 Relative tags from ChIPSeq indicate three states of RNAPII. (a) The average Ser5P RNAPII enrichment tags per one gene from
ChIPseq data, normalized to input by Peakseq, were summed according to their shifted positions with the definition that gene length was from
0 to 1. Where 0 represents the transcription start site and 1 represents the transcription end site. This indicated three states of RNAPII: Low
pausing and low elongation, high pausing and low elongation, and high pausing and high elongation. (b) Ser2P was also analyzed. No
significant enrichment was seen, except for Ser2P and Ser5P double positive genes.
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which the existence of phosphorylated RNAPII cannot
be proven. However, among the genes for which the
existence of phosphorylated RNAPII could be proven,
more than half of the genes for which the FPKM value
was one or less were Ser5P single positive. The probabil-
ity of Ser5P single positive genes increases until their
values of FPKM rise to about 6 (Figure 6). It can be said
that the genes whose FPKM is relatively high have an
unexpected high possibility of being judged as ‘pausing’
genes. The number of genes associated with Ser2P/
Ser5P double positive RNAPII increased with increasing
FPKM value, finally reaching 90 percent or more. Our
analysis presumes a qualitative value, like the phosphor-
ylation of Ser2 and Ser5, from a various amounts of
gene expression (FPKM). Although each group’s
borderline, which inclines sideways in the probability
plot of the logistic regression analysis, indicates the exis-
tence of another factor, it seems that the phosphoryla-
tion of RNAPII correlates with the gene expression
level. This is the first model of various mRNA expres-
sions using epigenetic factors. Ultimately, the amount of
mRNA expression could be explained using a similar
model in combination with other epigenetic factors,
such as transcription factors and histone modification.
Conclusions
We studied the association between mRNA expression
level and RNAPII phosphorylation state in Hela cells
using a deep sequencer for RNAseq and ChIPseq analy-
sis. During verification to improve the accuracy of
Table 2 Logistic regression analysis for RNAPII CTD phosphorylation Whole model test
Model Log likelihood DF Chi-square Prob > ChiSq




Observations (or sum weights) 13462
Parameter estimates




Intercept [S2P- S5P-] 0.6877 0.0445 238.89 < 0.0001 0.6005 0.7749
log2(FPKM+1) [S2P- S5P-] -0.4149 0.0158 691.98 < 0.0001 -0.4458 -0.384
Intercept [S2P+ S5P+] -0.2791 0.0412 45.89 < 0.0001 -0.3599 -0.1984
log2(FPKM+1) [S2P+ S5P+] 0.2127 0.0105 410.32 < 0.0001 0.1921 0.2333





















S2P and S5P double positive
S5P single positive
Figure 6 Nominal logistic fit of RNAPII phosphorylation state by FPKM on log scale. All FPKM > 0 genes were analyzed (n = 13462). To
avoid using the log of 0, we added 1 to each of the FPKM values prior to calculating logs.
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RNAseq, we found that the correlation between RNAseq
and past expression microarray data could be increased
by adjusting the ‘Max multihits’ parameter. We opti-
mized this parameter such that it minimized the risk of
reading genes that are not simultaneously expressed.
We also produced an antibody against the phosphory-
lated form of RNAPII, which allowed the genome-wide
visualization of the state of RNAPII phosphorylation
using ChIPseq. RNAseq and ChIPseq showed a very
high correlation, and the existence of RNAPII on
approximately 82% of genes that were detected with
RNAseq was confirmed in ChIPseq. In addition, when
we examined the relationship between the phosphoryla-
tion state of RNAPII and the level of mRNA expression,
phosphorylation of both Ser2 and Ser5 of RNAPII was
confirmed for almost all highly expressing genes. When
only Ser5 of PNAPII was phosphorylated, low mRNA
expression was detectable by RNAseq, in spite of the
pausing state. Moreover, when tag counts of Ser5P were
counted for genes identified only with RNAseq, the exis-
tence of a slightly higher level of Ser5P was detected
compared with the negative control. This indicated that
transcriptional adjustment is performed in two stages:
promoter escape and active elongation. We also provide
a hypothesis that gene expression can be classified into




Hela cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum under a humidified atmosphere with 5% CO2 at
37°C.
Production of rat monoclonal antibodies
The RNA polymerase II (RNAPII) Ser2P and Ser5P anti-
gens were synthesized based on their specific sequences,
Ser2P: SPTSPSYSphPTSPSYSPTSPS and Ser5P:
SPTSPSYSPTSphPSYSPTSPS (Sigma-Aldrich). A C-
terminal cysteine residue that was not part of the
sequence was introduced to allow coupling to the car-
rier protein maleimide-activated keyhole limpet hemo-
cyanin (Thermo Scientific). The coupling reaction was
performed according to the supplier’s instructions. Rat
monoclonal antibodies were generated based on the rat
lymph node method established by Sado et al. [29]. A
10-week-old female lzm rat (Japan SLC) was injected in
the rear footpads with 500 μl of an emulsion containing
200 μg RNAP2 Ser2P or Ser5P peptide and Freund’s
complete adjuvant. After two weeks, the cells from the
lymph nodes of the immunized rat were fused with
mouse myeloma Sp2/0-Ag14 cells at a ratio of 5:1 in
50% polyethylene glycol (Merck) solution. The resulting
hybridoma cells were plated onto 96-well plates and cul-
tured in HAT selection medium [hybridoma SFM med-
ium (Invitrogen); 10% fetal bovine serum; 10% BM-
Condimed H1 (Roche); 100 μM hypoxanthine; 0.4 μM
aminopterin; 1.6 μM thymidine]. At seven days post-
fusion, the hybridoma supernatants were screened using
an enzyme-linked immunosorbent assay (ELISA) against
each antigen. Positive clones were subcloned and
rescreened by ELISA (Table 1). To prepare hybridoma
supernatants containing highly concentrated antibodies,
the resulting positive clones, 3E7C7 for RNAP2 Ser2P
and 1H4B6 for RNAP2 Ser5P, were cultured at a high
cell density using a MiniPERM bioreactor (Vivascience).
ELISA
BSA conjugated RNAPII Ser2P or Ser5P peptides (5 μg/
mL) at dilutions ranging from 1:100 to 1:100000 in
ELISA buffer [10 mM sodium phosphate pH7.0] were
adsorbed on the surface of 96-well costar Serocluster 96
Well “U” Bottom Plates (Corning) by overnight incuba-
tion at 4°C. To avoid non-specific binding, the plates
were blocked with 1% bovine serum albumin (BSA) in
PBS. Hybridoma supernatants were applied to the plates
and incubated for 1 h at room temperature and then
washed three times with PBS. The plates were incubated
for 30 min at room temperature with alkaline phospha-
tase-conjugated anti-rat IgG antibody (Sigma) at a dilu-
tion of 1:10000. After washing three times with TBS-T,
immunoreactivity was visualized using a pNPP phospha-
tase substrate system (KPL).
Immunoblotting
Hela cells were washed twice with phosphate buffered
saline (PBS), centrifuged, and then resuspended in 2 ×
SDS sample buffer. The samples were separated by SDS-
PAGE and transferred to a nitrocellulose membrane
with iBlot (Invitrogen). The membrane was blocked for
1 h in 5% (w/v) skimmed milk in Tris-buffered saline
containing 0.05% (v/v) Tween 20 (TBST), then incu-
bated with primary antibodies in solution 1 (TOYOBO).
The blot was then incubated with horseradish peroxi-
dase-labeled secondary antibodies and detected using
the WestDura chemiluminescence kit (Pierce). The pri-
mary antibodies were anti-RNAPII Ser2P (3E7C7, hybri-
doma supernatant, 1:1000; Figure 2B and Table 1), anti-
RNAPII Ser5P (1H4B6, hybridoma supernatant, 1:1000;
Figure 2B and Table 1), and sc-899, the antibody against
the N-terminus of RNAPII (1:1000; Figure 2B). Second-
ary antibodies were horseradish peroxidase-conjugated
anti-rat IgG antibodies (1:5000; GE Healthcare).
Quantitative RT-PCR
Total RNA was isolated and reversed-transcribed with
Takara Prime Script Reverse Transcriptase and an oligo
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dT primer, as previously described [30]. Quantitative-
PCR (Q-PCR) was performed using TaKaRa SYBR Pre-
mix Dimer Eraser. Q-PCR data are presented as the
mean ± standard deviation of three independent experi-
ments. Primer sequences are available upon request.
RNASeq
Libraries were generated by the modified Illumina pro-
tocol using the mRNAseq preparation kit. Briefly, 1 μg
of total RNA was enriched for polyA RNA by two suc-
cessive rounds of oligo(dT) selection. The polyA RNA
was then fragmented, and first-strand cDNA synthesis
was performed using random hexamer priming. Follow-
ing second-strand cDNA synthesis, dsDNA was repaired
using T4 DNA polymerase, Klenow enzyme, and T4
polynucleotide kinase (PNK) (New England Biolabs), fol-
lowed by treatment with Klenow exo- to add an A base
to the 3’ end. After ligation of the Solexa adaptor using
TaKaRa ligation Mix (TaKaRa), the adaptor-ligated
DNAs were amplified using Solexa PCR primers for 18
cycles, and the amplified library was isolated from an
agarose gel. The samples were purified using the QIA-
quick MinElute kit (Qiagen) at each preparation step.
RNASeq data analysis
For each sample, cDNA was sequenced (single 36 bp
read) by an Illumina Genome Analyzer GAIIx. The
base-called sequences were obtained using SCS2.7 from
RNAseq image data. To calculate the total amount of
the transcripts of each mRNA, a series of programs-
Bowtie [31], TopHat (v1.1.4) [18], and Cufflinks (v0.9.3)
[19]-were used. Briefly, RNAseq reads were mapped
against the whole reference genome (hg19) using Bow-
tie. The reads that did not align to the genome but were
mapped to potential splice junctions by TopHat were
considered to bridge splice junctions. The quantification
of transcripts, with normalization for gene length, was
performed by Cufflinks. All of the parameters, except
‘Max multihits’ (TopHat), were substituted with default
options (TopHat: -g options as utilized as “multihits”.
Cufflinks: default suggested as -m 230 -s 20 -I 300000).
The ‘Max multihits’ was set at 1, 2, 5, 10, 20, 40, 100,
and 1000, and then the number of FPKM > 0 genes was
determined (Figure 1A, Additional File 2, Figure S2).
The Spearman’s correlation coefficients with microarray
data (Figure 1B), the percentage of splice sites that were
included in the gene body (Figure 1C), and histograms
of FPKM distributions at three ‘Max multihits’ values
(Figure 1D) were plotted.
Gene ontology and Fishers’ exact test
For the analysis, we used Funcassociate 2 [32], which is
a web application tool http://llama.mshri.on.ca/funcas-
sociate/ that finds significant Gene ontology terms from
large-scale experimentation. All of the parameters were
substituted with default options, i.e. Mode:unordered,
Over/Under:over, Simulations:1000, and Significance
Cutoff:0.05.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed by modifying the Upstate
Biotechnology protocol, as described previously [33]
except adding 40 mM b-glycerophosphate and 1 mM
sodium fluoride to immunoprecipitation buffer, utilizing
rat monoclonal antibodies against RNAPII Ser2P
(3E7C7, 5 μg; Figure 2B and Table 1) and RNAPII
Ser2P (3E7C7, 5 μg; Figure 2B and Table 1). Relative
recruitment (Figure 3C) was defined as the ratio of
amplification of the PCR product relative to 1% of input
genomic DNA. Q-PCR data are presented as the mean
± standard deviation of three independent experiments.
We designed PCR primers for gene regions within the 3
kb downstream of the 5’-start of each gene and within
the 3 kb upstream of the 3’-end of each gene because
Ser5 phosphorylated RNAPII is positioned in the coding
region at +2 to +4 kb from start site, as well as
upstream of start site [12]. Coding regions were used to
prevent any effects from neighboring genes. Primer
sequences are available upon request.
ChIPSeq
For ChIPseq, sample preparation was performed using
the ChIP protocol described above. The ChIP DNA and
the Input DNA ends were repaired using T4 DNA poly-
merase, Klenow enzyme, and T4 polynucleotide kinase
(PNK) (New England Biolabs), followed by treatment
with Klenow exo- to add an A base to the 3’ end. After
ligation of the Solexa adaptor using TaKaRa ligation
Mix (TaKaRa), the adaptor-ligated DNAs were amplified
using Solexa PCR primers for 18 cycles, and the ampli-
fied library was isolated from an agarose gel. The sam-
ples were purified using the QIAquick MinElute kit
(Qiagen) at each preparation step. The purified library
was used for cluster generation and sequencing analysis
using the Genome Analyzer GAIIx (Illumina K. K.).
ChIPSeq data analysis
Base-called sequences were obtained using SCS2.7 from
ChIPseq image data. The sequence tags for RNAPII
Ser2P and Ser5P and Input were aligned to the human
genome (hg19) using Bowtie [31] software. Peak detec-
tion and identification of binding sites of RNAPII Ser2P
and Ser5P were obtained by correcting from Input DNA
using Peakseq software, as described previously [24].
The box plot of RNAPII Ser2P and Ser5P enriched
regions that were found in Peakseq when using the
threshold of P-value < 0.05, Q-value < 0.05 is shown in
Figure 3B. We defined RNAPII recruitment as positive if
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the box plot overlapped the gene body to create the
Venn diagram (Figure 3A, Additional File 2, Figure S2).
For the detection of the binding site of RNAPII Ser2P
and Ser5P, all tags normalized to input by Peakseq were
summed according to their shifted positions, with the
definition that a gene length was 1, and along the hori-
zontal axis. 0 indicates the TSS (Transcription start site)
and 1 indicates the TES (Transcription end site) (Figure
2C, 5 and Additional File 4, Figure S3).
Any experimental procedure in this study does not
contain any animal experiment.
Data availability
The raw illumina sequencing data are available from the
DNA Data Bank of Japan (DDBJ) with accession number
[DDBJ: DRA000363].
Logistic regression analysis
Logistic regression was used to estimate the probability
of each RNAPII CTP phosphorylation state across the
FPKM range. A logistic probability plot for RNAPII
state was also created. All calculations were performed
using JMP v 8.0.2 (SAS, Cary, NC) running under Win-
dows XP.
Additional material
Additional file 1: Supplementary Figure S1. mRNA expressions of
representative genes whose FPKM values were low. Their expressions
could be confirmed by PCR. We chose the low FPKM value genes at
random from the group in which the existence of phosphorylated
RNAPII could not be confirmed by ChIPseq.
Additional file 2: Supplementary Figure S2. (a) Venn diagram
summarizing the overlap between FPKM > 0 genes, Ser2P genes, and
Ser5P genes according the ‘Max multihits’ parameter. (b) A line graph
showing how many detected genes increase in each category when
‘Max multihits’ parameter increases from 1. Both (a) and (b) indicated
that when ‘Max multihits’ parameter increases, the number of genes
detected by RNAseq rises, mainly in the group RNAseq(+), Ser2P(-), Ser5P
(-).
Additional file 3: Supplementary Table S1. Significant GO terms for
each category. To investigate the functional relationship among pausing/
active genes and gene functions, we analyzed significant association
using Gene ontology and Fishers’ exact test. Though hundreds of GO
terms were judged to be significant for double positive (RNAseq+/-,
Ser2P+m Ser5P+) genes, for the other categories, significant GO terms
were merely found.
Additional file 4: Supplementary Figure S3. Relative tags from FPKM >
0/Ser2P(+)/Ser5P(-) genes in ChIPseq indicate their source as background
noise. When Ser5P (a) and Ser2P (b) tags were summed for genes with
FPKM > 0/Ser2P(+)/Ser5P(-), the tag count outside of the gene was
higher than for other gene categories. This may indicate that they were
picked up from the background noise generated by surrounding genes.
List of abbreviations
ChIP: chromatin immunoprecipitation; RNAPII: RNA polymerase II; CTD: C-
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